arrow
T

Takehiko Mori

keio university school of medicine
H指数:47
被引数:8,098

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluation of the UK Myeloma Research Alliance risk profile in transplant-ineligible multiple myeloma patients treated with novel agents

评估英国骨髓瘤研究联盟风险特征在移植不适用的新型药物治疗的复发性骨髓瘤患者中的应用

2026-09-060
PRE
Delayed-onset parkinsonism possibly associated with elranatamab treatment for relapsed/refractory multiple myeloma: a case report of a poorly characterized neurological event

延迟发作的帕金森综合征可能与复发/难治性多发性骨髓瘤的elranatamab治疗有关:一项关于一种特征不明确的神经系统事件的病例报告

2026-07-070
OAAI
Risk Factors for and Impact of Pre-Engraftment Syndrome on Outcomes Following Single-Unit Cord Blood Transplantation in Adults

成人单份脐带血移植后预植入期综合征的危险因素及其对预后的影响

2025-09-260
OAAI
Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis (JUL, 10.1007/s00277-024-05898-3, 2024)
2024-08-210
OA
Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis
2024-07-221
PRE
Allogeneic Hematopoietic cell Transplantation Using Alemtuzumab in Asian Patients with Inborn Errors of Immunity
2024-05-220
PRE
Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis
2024-02-282
OAAI
Comparison of Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus Umbilical Cord Blood Transplantation in Adult Patients with Aplastic Anemia

单倍体相合干细胞移植后环磷酰胺与脐血移植治疗再生障碍性贫血的比较

2023-12-015
PRE
Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free Survival
2021-09-012
PRE
Resignation and return to work in patients receiving allogeneic hematopoietic cell transplantation close up
2021-08-275
PREAI